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Dr.Wei Lu is a professor of School of Pharmacy at Fudan University, Shanghai, China. He received his Bachelor of pharmaceutical sciences in 2000 and Ph.D. of pharmaceutics in 2005 from Fudan University. After graduation, he worked as a lecturer at Fudan University (2005--2006). Dr. Lu took his post-doctoral training of molecular imaging at Department of Experimental Diagnostic Imaging, the University of Texas M.D. Anderson Cancer, USA (2006--2009) and was promoted to an instructor (2009--2010). He was then appointed as an assistant professor (tenure-track) of College of Pharmacy at the University of Rhode Island, USA (2010--2015) and was early promoted to an associate professor (tenured) in 2015. In the same year, Dr. Lu joined the faculty of Fudan University.

Dr. Lu has a multidisciplinary research background in nanomedicine and gene/drug delivery. His Ph.D. work focused on nanoparticulate brain drug delivery for glioma gene therapy and chemotherapy. His research at M.D. Anderson Cancer Center focused on nanotechnology for cancer molecular imaging and therapeutics. Dr. Lu successfully developed hollow gold nanospheres as a platform nanotechnology for photothermal ablation therapy, siRNA delivery, and photoacoustic imaging. While photothermal ablation therapy represents an attractive therapeutic strategy, it is effective to treat local cancer but less so in controlling metastasis. After joining the faculty at the University of Rhode Island, Dr. Lu started his independent research and put his effort into addressing this issue. He developed a combinatorial photothermal immunotherapy by using hollow CuS nanoparticles to effectively treat both primary and metastatic tumor in mouse models. Dr. Lu has been continuing his work on nanomedicine for cancer molecular imaging and immunotherapy since he moved to Fudan University.

Dr. Lu received awards of "National Youth Thousand Talents Plan" of China and the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning. His Ph.D. dissertation was awarded National Excellent Doctoral Dissertation by Ministry of Education and Academic Degrees Committee of the State Council of China in 2007. His research was supported by National Institute of Health (NIH) R01 Research Grant of which he was the principle investigator. His current research is sponsored by National Natural Science Foundation of China (NSFC). Dr. Lu has published over 50 peer-reviewed research and review papers in SCI journals including ACS Nano, Cancer Research, Clinical Cancer Research, Theranostics, Small, Journal of Controlled Release. One of his research publication in ACS Nano was elected as the highly cited paper from Essential Science Indicators of Web of Science. In addition to his research, Dr. Lu has been involved in teaching courses of Pharm.D. program in the US and graduate courses of Pharmaceutical Sciences, as well as mentoring master, Ph.D. students and post-doctoral fellow. Dr. Lu has actively provided extensive services to the scientific community. He has served as an *ad hoc* reviewer of NIH Study Sections for R01 and R21 research grants as well as reviewer for grants from NSFC. Dr. Lu has also been invited by China Academic Degrees and Graduate Education Development Center to review master or Ph.D. degree theses.
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